Skip to main content

Clinical benefits of intra-articular anakinra for arthrofibrosis.

Publication ,  Journal Article
Brown, CA; Toth, AP; Magnussen, B
Published in: Orthopedics
December 1, 2010

Postoperative inflammation and stiffness, as well as the struggle to achieve full range of motion (ROM), following knee surgery is a significant clinical challenge. Interleukin-1 is a crucial mediator of the inflammatory response and development of pathological conditions leading to chronic inflammation. We hypothesized that intra-articular injection of intra-articular anakinra, an IL-1 antagonist, would result in sustained improvements of chronic refractory arthrofibrosis and limited arthrofibrosis of the knee joint. We retrospectively reviewed 8 patients who underwent injection of intra-articular anakinra, 200 mg. Four patients (3 women, 1 man) had intra-articular anakinra for treatment of chronic refractory arthrofibrosis, and 4 patients (4 women) had intra-articular anakinra for limited arthrofibrosis. All 4 of the refractory arthrofibrosis patients had failed conservative treatment with intensive physical therapy, corticosteroid injections, and anti-inflammatory medication. Three of the 4 patients had failed a prior manipulation under anesthesia with lysis of adhesions. All 4 reported improvement in ROM (10°-45°) and swelling, with 75% reporting improvement in pain. Seventy-five percent of these patients returned to prior activity level. All 4 of the limited arthrofibrosis also failed similar attempts at conservative treatment, and 2 of the 4 had failed a prior manipulation under anesthesia with lysis of adhesions. After intra-articular anakinra, all 4 reported improvement in ROM (20°-45°) and swelling, with 80% reporting improvement in pain. Seventy-five percent of these patients were able to return to prior activity level. We found intra-articular anakinra to be effective in this small cohort of patients with refractory arthrofibrosis and limited arthrofibrosis.

Duke Scholars

Published In

Orthopedics

DOI

EISSN

1938-2367

Publication Date

December 1, 2010

Volume

33

Issue

12

Start / End Page

877

Location

United States

Related Subject Headings

  • Young Adult
  • Orthopedics
  • Middle Aged
  • Male
  • Joints
  • Injections, Intra-Articular
  • Humans
  • Fibrosis
  • Female
  • Antirheumatic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Brown, C. A., Toth, A. P., & Magnussen, B. (2010). Clinical benefits of intra-articular anakinra for arthrofibrosis. Orthopedics, 33(12), 877. https://doi.org/10.3928/01477447-20101021-09
Brown, Christopher A., Alison P. Toth, and Bob Magnussen. “Clinical benefits of intra-articular anakinra for arthrofibrosis.Orthopedics 33, no. 12 (December 1, 2010): 877. https://doi.org/10.3928/01477447-20101021-09.
Brown CA, Toth AP, Magnussen B. Clinical benefits of intra-articular anakinra for arthrofibrosis. Orthopedics. 2010 Dec 1;33(12):877.
Brown, Christopher A., et al. “Clinical benefits of intra-articular anakinra for arthrofibrosis.Orthopedics, vol. 33, no. 12, Dec. 2010, p. 877. Pubmed, doi:10.3928/01477447-20101021-09.
Brown CA, Toth AP, Magnussen B. Clinical benefits of intra-articular anakinra for arthrofibrosis. Orthopedics. 2010 Dec 1;33(12):877.

Published In

Orthopedics

DOI

EISSN

1938-2367

Publication Date

December 1, 2010

Volume

33

Issue

12

Start / End Page

877

Location

United States

Related Subject Headings

  • Young Adult
  • Orthopedics
  • Middle Aged
  • Male
  • Joints
  • Injections, Intra-Articular
  • Humans
  • Fibrosis
  • Female
  • Antirheumatic Agents